Trial Profile
Phase I Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, PK, PD of CKD-504 in Single SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs CKD 504 (Primary)
- Indications Huntington's disease
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
- 06 Feb 2020 Planned End Date changed from 1 Feb 2020 to 1 Dec 2020.
- 06 Feb 2020 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2020.
- 26 Oct 2018 New trial record